S.Biomedics Balance Sheet Health
Financial Health criteria checks 5/6
S.Biomedics has a total shareholder equity of ₩8.0B and total debt of ₩9.7B, which brings its debt-to-equity ratio to 120.3%. Its total assets and total liabilities are ₩29.2B and ₩21.1B respectively.
Key information
120.3%
Debt to equity ratio
₩9.68b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩8.54b |
| Equity | ₩8.05b |
| Total liabilities | ₩21.14b |
| Total assets | ₩29.18b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A304360's short term assets (₩13.1B) exceed its short term liabilities (₩9.4B).
Long Term Liabilities: A304360's short term assets (₩13.1B) exceed its long term liabilities (₩11.7B).
Debt to Equity History and Analysis
Debt Level: A304360's net debt to equity ratio (14.2%) is considered satisfactory.
Reducing Debt: A304360's debt to equity ratio has increased from 25.6% to 120.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A304360 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A304360 is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.